
New study: vaccine therapy for treating patients with chronic leukaemia
Personalised peptide vaccination is expected to improve the treatment of patients with chronic lymphocytic leukaemia. A research team from Tübingen has started a Phase I clinical trial with CLL patients who will undergo ibrutinib treatment. Other leukaemia sufferers as well as cancer patients in general are also expected to benefit in the long term.
https://www.gesundheitsindustrie-bw.de/en/article/news/new-study-vaccine-therapy-treating-patients-chronic-leukaemia